Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Change in Receivables (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Change in Receivables for 16 consecutive years, with -$173000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 20.28% to -$173000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$110000.0 through Dec 2025, up 89.51% year-over-year, with the annual reading at -$110000.0 for FY2025, 89.51% up from the prior year.
  • Change in Receivables hit -$173000.0 in Q4 2025 for Perspective Therapeutics, down from -$46000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $618000.0 in Q3 2023 to a low of -$813000.0 in Q2 2024.
  • Historically, Change in Receivables has averaged -$68684.2 across 5 years, with a median of -$46000.0 in 2025.
  • Biggest five-year swings in Change in Receivables: soared 440.0% in 2021 and later tumbled 16700.0% in 2024.
  • Year by year, Change in Receivables stood at $68000.0 in 2021, then tumbled by 460.29% to -$245000.0 in 2022, then tumbled by 131.02% to -$566000.0 in 2023, then surged by 61.66% to -$217000.0 in 2024, then increased by 20.28% to -$173000.0 in 2025.
  • Business Quant data shows Change in Receivables for CATX at -$173000.0 in Q4 2025, -$46000.0 in Q3 2025, and $147000.0 in Q2 2025.